No Data
Sailong Pharmaceutical Group (002898.SZ): Voriconazole has received the approval notification for the listing application of Chemical Raw Materials.
Gelonghui, February 20, Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the approval notification for the listing application of Voriconazole as a Chemical Raw Material from the National Medical Products Administration. Voriconazole formulation is a broad-spectrum triazole antifungal agent primarily used to treat the following fungal infections: (1) Invasive aspergillosis. (2) Candidemia in patients with neutropenia. (3) Serious invasive infections caused by Candida species resistant to fluconazole (including Candida krusei). (4) Severe infections caused by the genera Scedosporium and Fusarium.
Cailong Pharmaceuticals: 2024 Annual Results Forecast
Sailong Pharmaceutical Group (002898.SZ): Net income for the 2024 fiscal year is expected to decline by 31.82% to 52.80%.
On January 21, Gelonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced its performance forecast for 2024, estimating a net income attributable to shareholders of the listed company of 4.5 million yuan to 6.5 million yuan, a decrease of 31.82% to 52.80% compared to the same period last year; the net income after deducting non-recurring gains and losses is expected to be 4.2 million yuan to 6.2 million yuan; the basic EPS is expected to be 0.0256 yuan/share to 0.0369 yuan/share. In 2024, the company's net income attributable to shareholders of the listed company is expected to decline year-on-year, mainly due to a decrease of approximately 11.65 million yuan in non-recurring gains and losses compared to the same period last year.
Sailong Pharmaceutical Group (002898.SZ): Received the approval notice for the listing application of the Chemical Raw Materials Active Pharmaceutical Ingredient famotidine.
On January 1st, Gelonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the "Approval Notice for the Marketing Application of Chemical Raw Materials for Famotidine" issued by the National Medical Products Administration. Famotidine formulation is mainly used to treat upper gastrointestinal bleeding caused by digestive ulcers, as well as mucosal erosion and bleeding of the stomach and duodenum due to various causes other than tumors and esophageal or gastric varices.
Sailong Pharmaceutical Group (002898.SZ): Participating in the tenth batch of national Pharmaceutical centralized procurement, expected to win the bid.
On December 13, Glonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical (Changsha) Co., Ltd. (hereinafter referred to as "Changsha Sailong") participated in the bidding work organized by the Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") for the tenth batch of national centralized procurement of pharmaceuticals. Some of the company's products are expected to win bids in this centralized procurement.
Sailong Pharmaceutical Group (002898.SZ) has obtained the supplementary approval letter for Pregabalin Capsules.
Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently received...
Some Confidence Is Lacking In Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) As Shares Slide 29%
